Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial.

Fecha de publicación: 20/12/2023 Fecha Ahead of Print: 20/12/2023

Autores de IIS La Fe

Gema Miñana Escrivá

Autor
Pau Llacer Iborra

Autor
Luis Almenar Bonet

Autor
Alicia María Maceira González

Autor
Jose Luis Sanchis Aldas

Autor

Participantes ajenos a IIS La Fe

Santas E
Del Canto I
Cardells I
Fácila L
Núñez J
Myocardial-IRON Investigators

Grupos

Grupo de Investigación Clínica y Traslacional en Cardiología

Investigador Principal

Esther Roselló Lletí
Regeneración y Trasplante Cardíaco

Leader

Pilar Sepúlveda Sanchis

Abstract

AIMS: Iron deficiency (ID) is associated with an impaired cardiac function and remodelling in heart failure (HF). Treatment with ferric carboxymaltose (FCM) has been showed recently to improve biventricular systolic function and ventricular strain parameters in patients with HF with reduced ejection fraction and ID, but there is no evidence on the benefit of FCM on the left atrium (LA). In this study, we aimed to evaluate the effect of FCM on LA longitudinal strain (LA-LS). METHODS AND RESULTS: This is a post hoc subanalysis of a double-blind, placebo-controlled, randomized clinical trial that enrolled 53 ambulatory patients with HF, left ventricular ejection fraction (LVEF) < 50%, and ID [Myocardial-IRON trial (NCT03398681)], treated with FCM or placebo. Cardiac magnetic resonance-featured tracking (CMR-FT) strain changes were evaluated before and 7 and 30 days after randomization using linear mixed regression analysis. The median age of the sample was 68 years (interquartile range: 64-76), and 20 (69%) were men. Mean ± standard deviation of LVEF was 39 ± 11%, and most (97%) were in stable New York Heart Association class II. At baseline, mean LA-LS was -8.9 ± 3.5%. At 30 days, and compared with placebo, LA-LS significantly improved in those allocated to FCM treatment arm (LA-LS = -12.0 ± 0.5 and -8.5 ± 0.6, respectively; - ? 3.55%, P < 0.001). CONCLUSIONS: In patients with stable HF, LVEF < 50%, and ID, treatment with FCM was associated with short-term improvements in LA-LS assessed by CMR-FT. Future works should assess the potential benefit of iron repletion on LA function.

Datos de la publicación

ISSN/ISSNe:: 2055-5822, 2055-5822
Tipo:: Article
Páginas:: 1258-1262
DOI:: 10.1002/ehf2.14630
Factor de Impacto:: 0,797 SCImago ℠
Cuartil:: Q2 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Santas E:: Department of Cardiology, Hospital Clínico Universitario de Valencia, Universitat de València, INCLIVA, Valencia, Spain
Del Canto I:: Department of Cardiology, Hospital Clínico Universitario de Valencia, Universitat de València, INCLIVA, Valencia, Spain
Cardells I:: Department of Cardiology, Hospital de Manises, Valencia, Spain
Miñana G:: Department of Cardiology, Hospital Clínico Universitario de Valencia, Universitat de València, INCLIVA, Valencia, Spain

CIBER Cardiovascular, Valencia, Spain
Llàcer P:: Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain
Almenar L:: Department of Cardiology, Hospital Universitario La Fe de Valencia, Valencia, Spain
Fácila L:: Department of Cardiology, Hospital General Universitario de Valencia, Valencia, Spain
Maceira AM:: Cardiovascular Imaging Unit, Ascires Biomedical Group, Valencia, Spain
Sanchis J:: Department of Cardiology, Hospital Clínico Universitario de Valencia, Universitat de València, INCLIVA, Valencia, Spain

CIBER Cardiovascular, Valencia, Spain
Núñez J:: Department of Cardiology, Hospital Clínico Universitario de Valencia, Universitat de València, INCLIVA, Valencia, Spain

CIBER Cardiovascular, Valencia, Spain